Top

Cardiovascular Intervention and Therapeutics

Published in:

01-01-2014 | Original Article

Catheter closure of patent foramen ovale in patients with cryptogenic cerebrovascular accidents: initial experiences in Japan

Authors: Yasufumi Kijima, Teiji Akagi, Koji Nakagawa, Manabu Taniguchi, Akira Ueoka, Kentaro Deguchi, Norihisa Toh, Hiroki Oe, Kengo Kusano, Shunji Sano, Hiroshi Ito

Published in: Cardiovascular Intervention and Therapeutics | Issue 1/2014

Abstract

Although numerous studies have shown an association between a patent foramen ovale (PFO) and cryptogenic cerebrovascular accidents (CVA), there has been no definitive control study that demonstrated the benefit of percutaneous device closure of a PFO compared to medical therapy in patients with CVA. Additionally, few clinical data exist for Japanese patients in this field. We demonstrate the initial experiences in catheter closure of a PFO as secondary prevention of CVA in Japan. Catheter closure of a PFO was attempted in 7 patients who were diagnosed with cryptogenic CVA. Mean age at the procedure was 54 ± 19 years. The presence of spontaneous interatrial right-to-left shunts was demonstrated by transesophageal contrast echocardiography without Valsalva maneuver in all of the patients. Amplatzer Cribriform device (n = 4) or Amplatzer PFO Occluder (n = 3) was used for the procedure and was successfully deployed. Device-related complications were not observed at the time of the procedure or during the follow-up period (mean period of 16 ± 9 months). Catheter closure of a PFO could be safely performed with Amplatzer Cribriform or Amplatzer PFO Occluder. This procedure may contribute to prevention of recurrent cryptogenic CVA in Japanese patients.

Oho S, Ishizawa A, Akagi T, Dodo H, Kato H. Transcatheter closure of atrial septal defects with the Amplatzer septal occluder—a Japanese clinical trial. Circ J. 2002;66:791–4.PubMedCrossRef

Kijima Y, Akagi T, Taniguchi M, Nakagawa K, Deguchi K, Tomii T, et al. Catheter closure of atrial septal defect in patients with cryptogenic stroke: initial experience in Japan. Cardiovasc Interv Ther. 2012;27:8–13.PubMedCrossRef

Hara H, Nakayama T, Matsuura H, Sato K, Hashimoto G, Yoshikawa H, et al. Transcatheter atrial septal defect closure in a patient with paradoxical brain emboli: who should treat it and who should be treated? Cardiovasc Interv Ther. 2012;27:8–13.CrossRef

Hagen PT, Scholz DG, Edwards WD. Incidence and size of patent foramen ovale during the first 10 decades of life: an autopsy study of 965 normal hearts. Mayo Clin Proc. 1984;59:17–20.PubMedCrossRef

Webster MW, Chancellor AM, Smith HJ, Swift DL, Sharpe DN, Bass NM, et al. Patent foramen ovale in young stroke patients. Lancet. 1988;2:11–2.PubMedCrossRef

Lechat P, Mas JL, Lascault G, Loron P, Theard M, Klimczac M, et al. Prevalence of patent foramen ovale in patients with stroke. N Engl J Med. 1988;318:1148–52.PubMedCrossRef

Mas JL, Arquizan C, Lamy C, Zuber M, Cabanes L, Derumeaux G, et al. Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both. N Engl J Med. 2001;345:1740–6.PubMedCrossRef

Overell JR, Bone I, Lees KR. Interatrial septal abnormalities and stroke: a meta-analysis of case–control studies. Neurology. 2000;55:1172–9.PubMedCrossRef

Furlan AJ, Reisman M, Massaro J, Mauri L, Adams H, Albers GW, et al. Closure or medical therapy for cryptogenic stroke with patent foramen ovale. N Engl J Med. 2012;366:991–9.PubMedCrossRef

10.

Bruch L, Parsi A, Grad MO, Rux S, Burmeister T, Krebs H, et al. Transcatheter closure of interatrial communications for secondary prevention of paradoxical embolism: single-center experience. Circulation. 2002;105:2845–8.PubMedCrossRef

11.

Braun MU, Fassbender D, Schoen SP, Haass M, Schraeder R, Scholtz W, et al. Transcatheter closure of patent foramen ovale in patients with cerebral ischemia. J Am Coll Cardiol. 2002;39:2019–25.PubMedCrossRef

12.

Khairy P, O’Donnell CP, Landzberg MJ. Transcatheter closure versus medical therapy of patent foramen ovale and presumed paradoxical thromboemboli: a systematic review. Ann Intern Med. 2003;139:753–60.PubMedCrossRef

13.

Silvestry FE, Naseer N, Wiegers SE, Hirshfeld JW, Herrmann HC. Percutaneous transcatheter closure of patent foramen ovale with the Amplatzer Cribriform septal occluder. Catheter Cardiovasc Interv. 2008;71:383–7.PubMedCrossRef

14.

Akhondi A, Gevorgyan R, Tseng CH, Slavin L, Dao C, Liebeskind DS, et al. The association of patent foramen ovale morphology and stroke size in patients with paradoxical embolism. Circ Cardiovasc Interv. 2010;3:506–10.PubMedCrossRef

15.

Ueno Y, Iguchi Y, Inoue T, Shibazaki K, Urabe T, Kimura K. Paradoxical brain embolism may not be uncommon—prospective study in acute ischemic stroke. J Neurol. 2007;254:763–6.PubMedCrossRef

16.

Homma S, Sacco RL, Di Tullio MR, Sciacca RR, Mohr JP. Effect of medical treatment in stroke patients with patent foramen ovale: patent foramen ovale in Cryptogenic Stroke Study. Circulation. 2002;105:2565–631.CrossRef

17.

Kizer JR, Devereux RB. Clinical practice. Patent foramen ovale in young adults with unexplained stroke. N Engl J Med. 2005;353:2361–72.PubMedCrossRef

18.

Handke M, Harloff A, Olschewski M, Hetzel A, Geibel A. Patent foramen ovale and cryptogenic stroke in older patients. N Engl J Med. 2007;357:2262–8.PubMedCrossRef

19.

Schwerzmann M, Windecker S, Wahl A, Mehta H, Nedeltchev K, Mattle H, et al. Percutaneous closure of patent foramen ovale: impact of device design on safety and efficacy. Heart. 2004;90:186–90.PubMedCrossRef

20.

Braun M, Gliech V, Boscheri A, Schoen S, Gahn G, Reichmann H, et al. Transcatheter closure of patent foramen ovale (PFO) in patients with paradoxical embolism. Periprocedural safety and mid-term follow-up results of three different device occluder systems. Eur Heart J. 2004;25:424–30.PubMedCrossRef

21.

Hara H, Virmani R, Ladich E, Mackey-Bojack S, Titus JL, Karnicki K, et al. Patent foramen ovale: standards for a preclinical model of prevalence, structure, and histopathologic comparability to human hearts. Catheter Cardiovasc Interv. 2007;69:266–73.PubMedCrossRef

22.

Zhang CJ, Huang YG, Huang XS, Huang T, Huang WH, Shen JJ. Transcatheter closure of patent foramen ovale in Chinese patients with paradoxical embolism. Immediate results and long-term follow-up. Circ J. 2011;75:1867–71.PubMedCrossRef

23.

Verma SK, Tobis JM. Explantation of patetent foramen ovale closure devices: a multicenter survey. JACC Cardiovasc Interv. 2011;4:579–85.PubMedCrossRef

24.

Spies C, Timmermanns I, Reissmann U, Van Essen J, Schrader R. Patent foramen ovale closure with the Intrasept occluder: complete 6–56 months follow-up of 247 patients after presumed paradoxical embolism. Catheter Cardiovasc Interv. 2008;71:390–5.PubMedCrossRef

25.

Windecker S, Wahl A, Nedeltchev K, Arnold M, Schwerzmann M, Seiler C, et al. Comparison of medical treatment with percutaneous closure of patent foramen ovale in patients with cryptogenic stroke. J Am Coll Cardiol. 2004;44:750–8.PubMedCrossRef

26.

Schuchlenz HW, Weihs W, Berghold A, Lechner A, Schmidt R. Secondary prevention after cryptogenic cerebrovascular events in patients with patent foramen ovale. Int J Cardiol. 2005;101:77–82.PubMedCrossRef

27.

Thanopoulos BV, Dardas PD, Karanasios E, Mezilis N. Transcatheter closure versus medical therapy of patent foramen ovale and cryptogenic stroke. Catheter Cardiovasc Interv. 2006;68:741–6.PubMedCrossRef

28.

Wahl A, Jüni P, Mono ML, Kalesan B, Praz F, Geister L, et al. Long-term propensity score-matched comparison of percutaneous closure of patent foramen ovale with medical treatment after paradoxical embolism. Circulation. 2012;125:803–12.PubMedCrossRef

29.

Agarwal S, Bajaj NS, Kumbhani DJ, Tuzcu EM, Kapadia SR. Meta-analysis of transcatheter closure versus medical therapy for patent foramen ovale in prevention of recurrent neurological events after presumed paradoxical embolism. JACC Cardiol Interv. 2012;5:777–89.CrossRef

30.

Rigatelli G, Dell’Avvocata F, Cardaioli P, Giordan M, Braggion G, Aggio S, et al. Permanent right-to-left shunt is the key factor in managing patent foramen ovale. J Am Coll Cardiol. 2011;58:2257–61.PubMedCrossRef

Title: Catheter closure of patent foramen ovale in patients with cryptogenic cerebrovascular accidents: initial experiences in Japan
Authors: Yasufumi Kijima
Teiji Akagi
Koji Nakagawa
Manabu Taniguchi
Akira Ueoka
Kentaro Deguchi
Norihisa Toh
Hiroki Oe
Kengo Kusano
Shunji Sano
Hiroshi Ito
Publication date: 01-01-2014
Publisher: Springer Japan
Published in: Cardiovascular Intervention and Therapeutics / Issue 1/2014
Print ISSN: 1868-4300
Electronic ISSN: 1868-4297
DOI: https://doi.org/10.1007/s12928-013-0193-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Catheter closure of patent foramen ovale in patients with cryptogenic cerebrovascular accidents: initial experiences in Japan

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2014

Delayed plaque protrusion after carotid artery stenting for the patient with symptomatic bi-lateral carotid artery stenosis

Integrity of stent polymer layer after drug-eluting stent implantation: in vivo comparison of sirolimus-, paclitaxel-, zotarolimus- and everolimus-eluting stents

Usefulness of Corsair microcatheter to cross stent struts in bifurcation lesions

Utility of nicorandil for the measurement of coronary fractional flow reserve

Serial three-dimensional optical coherence tomography assessment of strut coverage and intraluminal structures after drug-eluting stent implantation

Potential cause of delayed strokes following carotid artery stenting